CHANG, Gregory P.,CHEUNG, Ann F.,HANEY, William,LUNDE, Bradley M.,PRINZ, Bianka
申请号：
AU2018331412
公开号：
AU2018331412A1
申请日:
2018.09.13
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The invention provides multi-specific binding proteins that bind to a tumor-associated antigen CLEC12A and to the NKG2D receptor and CD16 receptor on natural killer cells. One aspect of the invention provides a protein that incorporates a first antigen-binding site that binds NKG2D； a second antigen-binding site that binds CLEC12A； and an antibody Fc domain, a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16. The antigen-binding sites may each incorporate an antibody heavy chain variable domain and an antibody light chain variable domain, or one or more of the antigen-binding sites may be a single domain antibody, such as a VHH antibody or a VNAR antibody. Another aspect of the invention provides a method of treating cancer in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of the multi-specific binding protein.
